Published in Am J Hematol on May 01, 1999
How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol (2015) 0.87
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? Curr Cardiol Rev (2010) 0.80
Mouse Pitx2 deficiency leads to anomalies of the ventral body wall, heart, extra- and periocular mesoderm and right pulmonary isomerism. Development (1999) 2.57
Successful treatment of a patient with febrile, lobular panniculitis (Weber-Christian disease) with oral cyclosporin A: implications for pathogenesis and therapy. Intern Med (1999) 1.70
Acute promyelocytic leukemia with marrow fibrosis at initial presentation: possible involvement of transforming growth factor-beta(1). Acta Haematol (2000) 1.66
Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest (2001) 1.19
Diminution of contractile response of the aorta from endotoxin-injected rats. Eur J Pharmacol (1987) 1.14
Modulation of vascular tonus by the endothelium in experimental diabetes. Life Sci (1987) 1.07
Effect of aging on endothelium-dependent vascular relaxation of isolated human basilar artery to thrombin and bradykinin. Stroke (1990) 1.03
Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant (2001) 1.02
Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol (2000) 1.01
Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant (2000) 0.95
The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology (2001) 0.94
Phase II study of FK 506 for allogeneic bone marrow transplantation. Transplant Proc (1991) 0.90
Modification of dopamine release by nociceptin in conscious rat striatum. Brain Res (1998) 0.89
Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med (2006) 0.89
High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. J Immunol (1992) 0.89
Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res (1999) 0.89
New imaging findings in a patient with central nervous system dysfunction after bone marrow transplantation. Acta Haematol (2000) 0.89
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. Int Angiol (1993) 0.88
Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation. Bone Marrow Transplant (1999) 0.88
Mechanism of hematuria in glomerular disease. An electron microscopic study in a case of diffuse membranous glomerulonephritis. Nephron (1983) 0.87
Extracellular pH affects platelet aggregation associated with modulation of store-operated Ca(2+) entry. Thromb Res (2001) 0.87
Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol (1997) 0.86
Intestinal blood flow at various intraluminal pressures in the piglet with closed abdomen. Ann Surg (1980) 0.85
Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells. Brain Res Mol Brain Res (2000) 0.84
Impairment of endothelium-dependent relaxation in human basilar artery after subarachnoid hemorrhage. Stroke (1992) 0.84
[A case of pyogenic granuloma in the sigmoid colon]. Nihon Shokakibyo Gakkai Zasshi (1995) 0.84
Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol (2000) 0.83
Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. Thromb Res (1990) 0.83
Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient. Bone Marrow Transplant (1997) 0.83
Scrotal ulcer occurring in patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Oncol Rep (1999) 0.83
A new rapid and simple assay for factor XIII activity using dansylcadaverine incorporation and gel filtration. Thromb Res (1984) 0.83
Fas ligand-induced caspase-1-dependent accumulation of interleukin-18 in mice with acute graft-versus-host disease. Blood (2001) 0.82
Thrombotic microangiopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant (1999) 0.82
Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant (2003) 0.82
The effects of thoracic aortic cross-clamping and declamping on visceral organ blood flow. Ann Surg (1983) 0.82
[Neuron specific enolase-producing IgD multiple myeloma with high serum amylase activity]. Rinsho Ketsueki (1995) 0.81
Antiserum to endotoxin in hemorrhagic shock. J Surg Res (1988) 0.81
Quantitative and continuous analysis of ATP release from blood platelets with firefly luciferase luminescence. Thromb Haemost (1985) 0.81
Effect of aging on contractile response to KCl, norepinephrine and 5-hydroxytryptamine in isolated human basilar artery. Gen Pharmacol (1992) 0.81
Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis (1999) 0.81
Heterogeneous expression of glycoprotein Ib, IX and V in platelets from two patients with Bernard-Soulier syndrome caused by different genetic abnormalities. Thromb Haemost (1995) 0.81
Regional myocardial blood flow in experimental myocardial infarction after pretreatment with aspirin. J Am Coll Cardiol (1986) 0.80
Two possible pathways for acquisition of mutations related to nelfinavir resistance. Jpn J Infect Dis (1999) 0.80
Small intestinal blood flow after 48 hours ileus, prostigmin and manual decompression. Z Exp Chir (1980) 0.80
Natriuretic peptides in water-deprived and in salt-loaded rats. Peptides (1996) 0.80
A case-control study on risk factors for leukemia in a district of Japan. Intern Med (1994) 0.80
A case of pulmonary amyloidosis associated with multiple myeloma successfully treated with dimethyl sulfoxide. Acta Haematol (1994) 0.80
Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis. Br J Haematol (1998) 0.79
Functional role of self IA molecules in polyclonal B cell activation using an autoreactive B cell clone derived from (NZB X NZW) F1 mice. Cell Immunol (1992) 0.79
FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant (1995) 0.79
Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant (2001) 0.79
Oral eicosapentaenoic acid for acute colonic graft-versus-host disease after bone marrow transplantation. Drugs Exp Clin Res (2002) 0.79
Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities. Acta Haematol (2000) 0.79
Direct interaction between an antigen-specific B cell clone and an MHC class II-reactive helper T cell clone. J Leukoc Biol (1992) 0.79
Destruction of immature erythrocytes measured by bilirubin excretion. Blood (1969) 0.79
Daunorubicin inhibits gene expression of cyclooxygenase-2 in vascular smooth muscle cells. Thromb Res (2001) 0.79
Interstitial pneumonitis after allogeneic bone marrow transplantation following total body irradiation. Radiat Med (1991) 0.78
Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells. Cell Immunol (1999) 0.78
Inhibitory effect of ethanol on endothelium-dependent vascular responsiveness. Eur J Pharmacol (1989) 0.78
Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway. Immunology (2000) 0.78
Stromal fibroblastic and hematopoietic progenitors in patients with graft-versus-host disease (GVHD). Int J Hematol (1991) 0.78
Adult respiratory distress syndrome-like disorders after allogeneic bone marrow transplantation. Transplantation (1999) 0.78
Changes in microbial flora in neutropenic patients with hematological disorders after the Hanshin-Awaji earthquake. Int J Hematol (2000) 0.78
Treatment of intestinal graft-versus-host disease using betamethasone enemas. Transplantation (2001) 0.77
IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement. Acta Haematol (2000) 0.77
Regulation of interleukin-6 and interleukin-6R alpha (gp80) expression by murine immunoglobulin-secreting B-cell hybridomas. Immunology (1998) 0.77
Increased expression of Fas (APO-1, CD95) on CD34+ haematopoietic progenitor cells after allogeneic bone marrow transplantation. Br J Haematol (2000) 0.77
The effect of oxygen on the development of atherosclerosis in WHHL rabbits. Atherosclerosis (1983) 0.77
Role of calcium in the potentiating effect of phorbol ester on KCl-induced vasocontraction. Biochem Biophys Res Commun (1988) 0.77
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation. Bone Marrow Transplant (2002) 0.77
Role of alveolar macrophage plasminogen activator in the acute pulmonary responses to endotoxin. Lung (1984) 0.77
Urinary trypsin inhibitor concentration can predict the immunological insult of chemotherapy and complications after bone marrow transplantation. Bone Marrow Transplant (2001) 0.77
[Application of heat-treated factor VII concentrates in a patient with congenital factor VII deficiency during labor]. Rinsho Ketsueki (1988) 0.77
Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res (2000) 0.77
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies. Ann Hematol (2000) 0.77
Does intravenous glutamine prevent bacterial translocation in hemorrhagic shock? Shock (1994) 0.76
Predicting the severity of intestinal graft-versus-host disease from leukotriene B4 levels after bone marrow transplantation. Bone Marrow Transplant (2000) 0.76
Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia (2000) 0.76
Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy. Drugs Exp Clin Res (2000) 0.76
Influence of Helicobacter pylori on platelets after bone marrow transplantation from unrelated donors. Bone Marrow Transplant (2003) 0.76
Exogenous nitric oxide inhibits platelet activation in whole blood. J Cardiovasc Pharmacol (1999) 0.76
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. Drugs Exp Clin Res (1999) 0.76
The molecular mechanism in activation-induced cell death of an Ag-reactive B cell clone. Clin Exp Immunol (2002) 0.76
Efficacy of the high molecular weight fraction of plasma for the maintenance of pregnancy associated with thrombotic thrombocytopenic purpura. Am J Hematol (1990) 0.76
Mechanism of the potentiating effect of NH4Cl on vasoconstriction in rat aorta. Gen Pharmacol (1996) 0.76
Androgen in the treatment of refractory anemia. Int J Hematol (1991) 0.76
Increased expression of Fas (APO-1, CD95) on CD4+ and CD8+ T lymphocytes during total body irradiation. Acta Haematol (2000) 0.76
Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. J Surg Res (1993) 0.76
Age related elevation of serum macrophage colony stimulating factor (M-CSF) level. Arch Gerontol Geriatr (2004) 0.76
Desensitization of alpha-1 adrenergic receptor mediated smooth muscle contraction in aorta from endotoxic rats. Life Sci (1989) 0.76